 |
News and Events 
Press Releases
- SCYNEXIS and Medicines for Malaria Venture Sign HEOS® Agreement
- SCYNEXIS’ SCY-635 Demonstrates Clinically Relevant Single-agent Results in a Phase 1b Study in Adults with HCV
- First Candidate from SCYNEXIS’ Novel Cyclophilin Inhibitor Platform, SCY 635, Establishes Proof of Concept in HCV-Infected Adults
- SCYNEXIS and DNDi Extend Collaboration to Identify Drug Candidates to Treat Sleeping Sickness
- SCYNEXIS to Present Preclinical HCV Data on Novel Cyclophillin Inhibitor SCY-635 at AASLD Annual Meeting
- SCYNEXIS Convenes Renowned Scientists for Symposium on the Therapeutic Promise of Cyclophilin Inhibitors
- SCYNEXIS, Inc. Completes $13.5 Million Financing
- Scynexis Receives Merial Research Collaboration Milestone Payment
- SCYNEXIS and DNDi Enter Landmark Multi-Year Agreement to Identify Drug Candidates to Treat Sleeping Sickness
- Merial-SCYNEXIS Research Collaboration Expanded
- SCYNEXIS, Inc. Receives Preclinical Milestone Payment In Collaboration with Merck
- SCYNEXIS announces research agreement with Merck for discovery of novel oncology agents
- SCYNEXIS announces new board chairman and new board member appointments of well-known pharmaceutical executives
- SCYNEXIS Europe is now Selcia following spin off from SCYNEXIS, Inc
- Teijin Pharma and SCYNEXIS Sign Research Agreement
- SCYNEXIS, Inc. Selected As a Primary Research Partner for Merial
- ADHEREX AND SCYNEXIS SIGN AGREEMENT TO ACCELERATE DESIGN OF SMALLMOLECULE CADHERIN ANTAGONISTS
- Norak Biosciences And SCYNEXIS Announce Chemistry Collaboration
- SCYNEXIS Signs A Drug Discovery Deal With Mitsubishi Pharma
- SCYNEXIS Announces Broadening of Research Agreement With Roche For Discovery Of Novel Central Nervous System And Metabolic Disease Agents
- MERCK, SCYNEXIS Announce Broadening Of Research Collaboration For Discovery Of Novel Anti-Infective Agents
- SCYNEXIS Announces Research Collaboration with Roche For Discovery of Novel Central Nervous System and Metabolic Disease Agents
- SCYNEXIS, Inc. Announces Research Collaboration with Merck & Co., Inc. For Discovery Of Novel Anti-infective Agents
- SCYNEXIS Completes $29 million New Round of Investment
- SCYNEXIS Closes First Round of Funding
Copyright © 2009. SCYNEXIS, INC